{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T17:57:33Z","timestamp":1792173453822,"version":"4.4.0"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,3,13]],"date-time":"2025-03-13T00:00:00Z","timestamp":1741824000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,3,13]],"date-time":"2025-03-13T00:00:00Z","timestamp":1741824000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"National Science Foundation","award":["DGE-2039655"],"award-info":[{"award-number":["DGE-2039655"]}]},{"DOI":"10.13039\/100000002","name":"National Institutes for Health","doi-asserted-by":"crossref","award":["P01AI165077"],"award-info":[{"award-number":["P01AI165077"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000002","name":"National Institutes for Health","doi-asserted-by":"crossref","award":["P01AI165077"],"award-info":[{"award-number":["P01AI165077"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["npj Viruses"],"DOI":"10.1038\/s44298-025-00101-4","type":"journal-article","created":{"date-parts":[[2025,3,13]],"date-time":"2025-03-13T05:34:28Z","timestamp":1741844068000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Potent bivalent nanobody constructs that protect against the SARS-CoV-2 XBB variant"],"prefix":"10.1038","volume":"3","author":[{"given":"Peter J.","family":"Halfmann","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeong Soo","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikki","family":"McArthur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ojas","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshihiro","family":"Kawaoka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ravi S.","family":"Kane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,13]]},"reference":[{"key":"101_CR1","doi-asserted-by":"publisher","first-page":"2376","DOI":"10.1002\/jmv.27643","volume":"94","author":"D Tian","year":"2022","unstructured":"Tian, D., Sun, Y., Xu, H. & Ye, Q. The emergence and epidemic characteristics of the highly mutated SARS-CoV-2 Omicron variant. J. Med. Virol. 94, 2376\u20132383 (2022).","journal-title":"J. Med. Virol."},{"key":"101_CR2","doi-asserted-by":"publisher","first-page":"980","DOI":"10.1016\/j.ijbiomac.2022.07.254","volume":"219","author":"C Chakraborty","year":"2022","unstructured":"Chakraborty, C., Bhattacharya, M., Sharma, A. R. & Mallik, B. Omicron (B.1.1.529)\u2014a new heavily mutated variant: mapped location and probable properties of its mutations with an emphasis on S-glycoprotein. Int. J. Biol. Macromol. 219, 980\u2013997 (2022).","journal-title":"Int. J. Biol. Macromol."},{"key":"101_CR3","doi-asserted-by":"publisher","unstructured":"Yang, J. S. et al. Molecular interaction and inhibition of SARS-CoV-2 binding to the ACE2 receptor (11, 4541, 2020). Nat. Commun. 12, ARTN 2996 https:\/\/doi.org\/10.1038\/s41467-021-23498-x (2021).","DOI":"10.1038\/s41467-021-23498-x"},{"key":"101_CR4","doi-asserted-by":"publisher","first-page":"2183","DOI":"10.1016\/j.cell.2021.02.032","volume":"184","author":"W Dejnirattisai","year":"2021","unstructured":"Dejnirattisai, W. et al. The antigenic anatomy of SARS-CoV-2 receptor binding domain. Cell 184, 2183\u20132200 e22 (2021).","journal-title":"Cell"},{"key":"101_CR5","doi-asserted-by":"publisher","first-page":"864","DOI":"10.1126\/science.abn8652","volume":"375","author":"M McCallum","year":"2022","unstructured":"McCallum, M. et al. Structural basis of SARS-CoV-2 Omicron immune evasion and receptor engagement. Science 375, 864\u2013868 (2022).","journal-title":"Science"},{"key":"101_CR6","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-46490-7","volume":"15","author":"D Planas","year":"2024","unstructured":"Planas, D. et al. Distinct evolution of SARS-CoV-2 Omicron XBB and BA.2.86\/JN.1 lineages combining increased fitness and antibody evasion. Nat. Commun. 15, 2254 (2024).","journal-title":"Nat. Commun."},{"key":"101_CR7","doi-asserted-by":"publisher","first-page":"e440","DOI":"10.1093\/cid\/ciab912","volume":"75","author":"M Dougan","year":"2022","unstructured":"Dougan, M. et al. A randomized, placebo-controlled clinical trial of bamlanivimab and etesevimab together in high-risk ambulatory patients with COVID-19 and validation of the prognostic value of persistently high viral load. Clin. Infect. Dis. 75, e440\u2013e449 (2022).","journal-title":"Clin. Infect. Dis."},{"key":"101_CR8","doi-asserted-by":"publisher","first-page":"e81","DOI":"10.1056\/NEJMoa2108163","volume":"385","author":"DM Weinreich","year":"2021","unstructured":"Weinreich, D. M. et al. REGEN-COV antibody combination and outcomes in outpatients with Covid-19. N. Engl. J. Med. 385, e81 (2021).","journal-title":"N. Engl. J. Med."},{"key":"101_CR9","unstructured":"Emergency Use Authorizations for Drugs and Non-Vaccine Biological Products. U.S. Food and Drug Administration; FDA. Updated September 26 2024. Accessed October 24, 2024. https:\/\/www.fda.gov\/drugs\/emergency-preparedness-drugs\/emergency-use-authorizations-drugs-and-non-vaccine-biological-products"},{"key":"101_CR10","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1038\/s41586-021-04385-3","volume":"602","author":"Y Cao","year":"2022","unstructured":"Cao, Y. et al. Omicron escapes the majority of existing SARS-CoV-2 neutralizing antibodies. Nature 602, 657\u2013663 (2022).","journal-title":"Nature"},{"key":"101_CR11","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1038\/s41591-021-01678-y","volume":"28","author":"LA VanBlargan","year":"2022","unstructured":"VanBlargan, L. A. et al. An infectious SARS-CoV-2 B.1.1.529 Omicron virus escapes neutralization by therapeutic monoclonal antibodies. Nat. Med. 28, 490\u2013495 (2022).","journal-title":"Nat. Med."},{"key":"101_CR12","first-page":"521","volume":"614","author":"Y Cao","year":"2023","unstructured":"Cao, Y. et al. Imprinted SARS-CoV-2 humoral immunity induces convergent Omicron RBD evolution. Nature 614, 521\u2013529 (2023).","journal-title":"Nature"},{"key":"101_CR13","unstructured":"FDA Announces Bebtelovimab is Not Currently Authorized in Any US Region. U.S. Food & Drug Administration. Accessed March 24, 2024. https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/fda-announces-bebtelovimab-not-currently-authorized-any-us-region"},{"key":"101_CR14","unstructured":"FDA announces Evusheld is not currently authorized for emergency use in the U.S. U.S. Food and Drug Administration; FDA. Accessed April 5, 2024. https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/fda-announces-evusheld-not-currently-authorized-emergency-use-us."},{"key":"101_CR15","unstructured":"FDA updates Sotrovimab emergency use authorization. U.S. Food and Drug Administration; FDA. Accessed October 24, 2024. https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/fda-updates-sotrovimab-emergency-use-authorization."},{"key":"101_CR16","first-page":"1982","volume":"331","author":"E Harris","year":"2024","unstructured":"Harris, E. Monoclonal antibody authorized to protect at-risk people from COVID-19. JAMA 331, 1982 (2024).","journal-title":"JAMA"},{"key":"101_CR17","doi-asserted-by":"crossref","unstructured":"Wang, Q., Guo, Y., Ho, J. & Ho, D. D. Activity of Research-Grade Pemivibart against recent SARS-CoV-2 JN.1 Sublineages. New Engl J. Med. 391, 1863\u20131864 (2024).","DOI":"10.1056\/NEJMc2410203"},{"key":"101_CR18","doi-asserted-by":"crossref","unstructured":"Planas, D. et al. Escape of SARS-CoV-2 variants KP1.1, LB.1, and KP3.3 from approved monoclonal antibodies. Pathog. Immun. 10, 1\u201311 (2024).","DOI":"10.20411\/pai.v10i1.752"},{"key":"101_CR19","doi-asserted-by":"publisher","first-page":"E47","DOI":"10.1016\/S1473-3099(22)00733-2","volume":"23","author":"P Arora","year":"2023","unstructured":"Arora, P., Kempf, A. & Nehlmeier, I. Omicron sublineage BQ.1.1 resistance to monoclonal antibodies. Lancet Infect. Dis. 23, E47\u2013E47 (2023).","journal-title":"Lancet Infect. Dis."},{"key":"101_CR20","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1038\/363446a0","volume":"363","author":"C Hamers-Casterman","year":"1993","unstructured":"Hamers-Casterman, C. et al. Naturally occurring antibodies devoid of light chains. Nature 363, 446\u2013448 (1993).","journal-title":"Nature"},{"key":"101_CR21","doi-asserted-by":"publisher","unstructured":"Jin, B. K., Odongo, S., Radwanska, M., Magez, S. Nanobodies: a. review of generation, diagnostics and therapeutics. Int. J. Mol. Sci. 24 https:\/\/doi.org\/10.3390\/ijms24065994 (2023).","DOI":"10.3390\/ijms24065994"},{"key":"101_CR22","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-018-26338-z","volume":"8","author":"P Kunz","year":"2018","unstructured":"Kunz, P. et al. The structural basis of nanobody unfolding reversibility and thermoresistance. Sci. Rep. 8, 7934 (2018).","journal-title":"Sci. Rep."},{"key":"101_CR23","doi-asserted-by":"publisher","unstructured":"Steeland, S., Vandenbroucke, R. E., Libert, C. Nanobodies as therapeutics: big opportunities for small antibodies. Drug Discov. Today. 21 https:\/\/doi.org\/10.1016\/j.drudis.2016.04.003 (2016).","DOI":"10.1016\/j.drudis.2016.04.003"},{"key":"101_CR24","doi-asserted-by":"publisher","first-page":"107085","DOI":"10.1016\/j.isci.2023.107085","volume":"26","author":"N Modhiran","year":"2023","unstructured":"Modhiran, N. et al. A nanobody recognizes a unique conserved epitope and potently neutralizes SARS-CoV-2 omicron variants. iScience 26, 107085 (2023).","journal-title":"iScience"},{"key":"101_CR25","doi-asserted-by":"publisher","unstructured":"Yao H. B. et al. A potent and broad-spectrum neutralizing nanobody for SARS-CoV-2 viruses, including all major Omicron strains. Medcomm. 4ARTN e397 https:\/\/doi.org\/10.1002\/mco2.397 (2023).","DOI":"10.1002\/mco2.397"},{"key":"101_CR26","doi-asserted-by":"publisher","unstructured":"Ma, H. et al. A bispecific nanobody dimer broadly neutralizes SARS-CoV-1 & 2 variants of concern and offers substantial protection against Omicron via low-dose intranasal administration. Cell Discov. 8, ARTN 132 https:\/\/doi.org\/10.1038\/s41421-022-00497-w (2022).","DOI":"10.1038\/s41421-022-00497-w"},{"key":"101_CR27","doi-asserted-by":"publisher","unstructured":"Yang, J. et al. Development of a bispecific nanobody conjugate broadly neutralizes diverse SARS-CoV-2 variants and structural basis for its broad neutralization. Plos Pathog. 19, ARTN e1011804 https:\/\/doi.org\/10.1371\/journal.ppat.1011804 (2023).","DOI":"10.1371\/journal.ppat.1011804"},{"key":"101_CR28","doi-asserted-by":"publisher","unstructured":"Solodkov, P. P. et al. Serial Llama immunization with various SARS-CoV-2 RBD variants induces broad spectrum virus-neutralizing nanobodies. Vaccines. 12, ARTN 129 https:\/\/doi.org\/10.3390\/vaccines12020129 (2024).","DOI":"10.3390\/vaccines12020129"},{"key":"101_CR29","doi-asserted-by":"publisher","unstructured":"Wang Z., et al. Broad-Spectrum Engineered Multivalent Nanobodies Against SARS-CoV-1\/2. Adv. Sci. 2402975. https:\/\/doi.org\/10.1002\/advs.202402975","DOI":"10.1002\/advs.202402975"},{"key":"101_CR30","doi-asserted-by":"publisher","first-page":"e1012625","DOI":"10.1371\/journal.ppat.1012625","volume":"20","author":"H Dong","year":"2024","unstructured":"Dong, H. et al. Super broad and protective nanobodies against Sarbecoviruses including SARS-CoV-1 and the divergent SARS-CoV-2 subvariant KP.3.1.1. Plos Pathog. 20, e1012625 (2024).","journal-title":"Plos Pathog."},{"key":"101_CR31","doi-asserted-by":"publisher","unstructured":"Liu, H. H. et al. Two pan-SARS-CoV-2 nanobodies and their multivalent derivatives effectively prevent Omicron infections in mice. Cell Rep. Med. 4, ARTN 100918 https:\/\/doi.org\/10.1016\/j.xcrm.2023.100918 (2023).","DOI":"10.1016\/j.xcrm.2023.100918"},{"key":"101_CR32","doi-asserted-by":"publisher","DOI":"10.1002\/EXP.20230086","author":"Y Yang","year":"2023","unstructured":"Yang, Y. et al. A novel nanobody broadly neutralizes SARS-CoV-2 via induction of spike trimer dimers conformation. Exploration https:\/\/doi.org\/10.1002\/EXP.20230086 (2023).","journal-title":"Exploration"},{"key":"101_CR33","doi-asserted-by":"publisher","unstructured":"Ye, G. et al. Discovery of Nanosota-2,-3, and-4 as super potent and broad-spectrum therapeutic nanobody candidates against COVID-19. J. Virol. ARTN e01448-23 https:\/\/doi.org\/10.1128\/jvi.01448-23 (2023).","DOI":"10.1128\/jvi.01448-23"},{"key":"101_CR34","doi-asserted-by":"publisher","unstructured":"Nagata, K. et al. Intratracheal trimerized nanobody cocktail administration suppresses weight loss and prolongs survival of SARS-CoV-2 infected mice. Commun Med. 2, ARTN 152 https:\/\/doi.org\/10.1038\/s43856-022-00213-5 (2022).","DOI":"10.1038\/s43856-022-00213-5"},{"key":"101_CR35","doi-asserted-by":"publisher","unstructured":"Favorskaya, I. A. et al. Single-domain antibodies efficiently neutralize SARS-CoV-2 variants of concern. Front. Immunol. 13, ARTN 822159 https:\/\/doi.org\/10.3389\/fimmu.2022.822159 (2022).","DOI":"10.3389\/fimmu.2022.822159"},{"key":"101_CR36","doi-asserted-by":"publisher","first-page":"1379","DOI":"10.1016\/j.ijbiomac.2022.04.096","volume":"209","author":"TT Li","year":"2022","unstructured":"Li, T. T. et al. Isolation, characterization, and structure-based engineering of a neutralizing nanobody against SARS-CoV-2. Int. J. Biol. Macromol. 209, 1379\u20131388 (2022).","journal-title":"Int. J. Biol. Macromol."},{"key":"101_CR37","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1038\/s41594-018-0028-6","volume":"25","author":"C McMahon","year":"2018","unstructured":"McMahon, C. et al. Yeast surface display platform for rapid discovery of conformationally selective nanobodies. Nat. Struct. Mol. Biol. 25, 289\u2013296 (2018).","journal-title":"Nat. Struct. Mol. Biol."},{"key":"101_CR38","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1126\/science.abb7269","volume":"368","author":"M Yuan","year":"2020","unstructured":"Yuan, M. et al. A highly conserved cryptic epitope in the receptor binding domains of SARS-CoV-2 and SARS-CoV. Science 368, 630\u2013633 (2020).","journal-title":"Science"},{"key":"101_CR39","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1038\/s41586-020-2349-y","volume":"583","author":"D Pinto","year":"2020","unstructured":"Pinto, D. et al. Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody. Nature 583, 290\u2013295 (2020).","journal-title":"Nature"},{"key":"101_CR40","doi-asserted-by":"crossref","unstructured":"McArthur N. et al. Development of a pan-tau multivalent nanobody that binds tau aggregation motifs and recognizes pathological tau aggregates. Biotechnol. Prog. e3463 (2024).","DOI":"10.1002\/btpr.3463"},{"key":"101_CR41","doi-asserted-by":"publisher","first-page":"113580","DOI":"10.1016\/j.celrep.2023.113580","volume":"42","author":"R Uraki","year":"2023","unstructured":"Uraki, R. et al. Characterization of a SARS-CoV-2 EG.5.1 clinical isolate in vitro and in vivo. Cell Rep. 42, 113580 (2023).","journal-title":"Cell Rep."},{"key":"101_CR42","unstructured":"CDC COVID Data tracker: variant proportions. centers for disease control and prevention. Updated 2024. Accessed November 10th, 2024. https:\/\/covid.cdc.gov\/covid-data-tracker\/#variant-proportions"},{"key":"101_CR43","doi-asserted-by":"publisher","first-page":"e13431","DOI":"10.1111\/imr.13431","volume":"329","author":"M Yuan","year":"2025","unstructured":"Yuan, M. & Wilson, I. A. Structural immunology of SARS-CoV-2. Immunol. Rev. 329, e13431 (2025).","journal-title":"Immunol. Rev."},{"key":"101_CR44","doi-asserted-by":"publisher","first-page":"6966","DOI":"10.1016\/j.cell.2024.09.043","volume":"187","author":"Y Xiang","year":"2024","unstructured":"Xiang, Y. et al. Adaptive multi-epitope targeting and avidity-enhanced nanobody platform for ultrapotent, durable antiviral therapy. Cell 187, 6966\u20136980.e23 (2024).","journal-title":"Cell"},{"key":"101_CR45","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/j.jmb.2013.09.016","volume":"426","author":"M Fairhead","year":"2014","unstructured":"Fairhead, M., Krndija, D., Lowe, E. D. & Howarth, M. Plug-and-play pairing via defined divalent streptavidins. J. Mol. Biol. 426, 199\u2013214 (2014).","journal-title":"J. Mol. Biol."},{"key":"101_CR46","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.ymeth.2012.03.014","volume":"60","author":"N Gera","year":"2013","unstructured":"Gera, N., Hussain, M. & Rao, B. M. Protein selection using yeast surface display. Methods 60, 15\u201326 (2013).","journal-title":"Methods"}],"container-title":["npj Viruses"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s44298-025-00101-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s44298-025-00101-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s44298-025-00101-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,13]],"date-time":"2025-03-13T05:34:33Z","timestamp":1741844073000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s44298-025-00101-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,13]]},"references-count":46,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["101"],"URL":"https:\/\/doi.org\/10.1038\/s44298-025-00101-4","relation":{},"ISSN":["2948-1767"],"issn-type":[{"value":"2948-1767","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,13]]},"assertion":[{"value":"18 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 February 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 March 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare the following competing interests: Y.K. has received unrelated funding support from Daiichi Sankyo Pharmaceutical, Toyama Chemical, Tauns Laboratories, Inc., Shionogi & Co. LTD, Otsuka Pharmaceutical, KM Biologics, Kyoritsu Seiyaku, Shinya Corporation, and Fuji Rebio. The other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"19"}}